Manufacturing issues delay AbbVie's Parkinson's drug

15 July 2024

AbbVie's potential treatment for Parkinson's disease, ABBV-951 (foscarbidopa/foslevodopa), has encountered another obstacle, as the FDA has issued a second complete response letter (CRL) for the drug in just over a year. This latest CRL pertains to manufacturing issues involving a third-party facility rather than the drug itself.

ABBV-951 is designed to address motor fluctuations in adults with advanced Parkinson's disease through a 24-hour continuous subcutaneous infusion of carbidopa and levodopa prodrugs. Neurologists have considered it a less invasive and cumbersome alternative to AbbVie's existing Duopa/Duodopa product, which requires an intraduodenal infusion.

Researching ABBV-951 beyond the basics?

Synapse Hiro LS Researcher, the Synapse AI Insight Engine, is built to accelerate biopharma decisions. Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence. Explore ABBV-951 with Hiro LS Researcher →

Synapse Hiro LS Researcher AI-powered pharmaceutical intelligence

In an update, AbbVie clarified that the FDA's concerns are unrelated to ABBV-951's safety, efficacy, or labeling, nor did the agency request additional clinical trials. The issues were discovered during an inspection of a third-party manufacturing facility involved in the new drug application. AbbVie emphasized that the inspection did not concern ABBV-951 or any of its other medications.

Last year in March, the FDA had already declined to approve the application, asking for more information about the infusion pump. According to Roopal Thakkar, AbbVie's chief medical officer of global therapeutics, there remains a significant unmet need for advanced Parkinson's disease treatments in the U.S. Thakkar stated that the company is committed to working with the FDA to make this important therapy available to patients as soon as possible.

ABBV-951 has already been approved in 34 countries, with over 2100 patients worldwide starting treatment. The therapy has generated significant interest in the medical community, with analysts predicting sales of $620 million by 2026 and $1.3 billion by 2028.

This development comes at a time when AbbVie is experiencing an unexpected surge in growth. Despite losing exclusivity for its blockbuster drug Humira (adalimumab) and the recent departure of its founding CEO, the company’s stock price has been rising. AbbVie's market cap recently surpassed that of Merck & Co., making it one of the more successful pharmaceutical companies this year.

Continue your ABBV-951 research with Synapse Hiro LS Researcher

This article provides an overview. For a broader research view, use Synapse Hiro LS Researcher—the Synapse AI Insight Engine—to search across drugs, targets, indications, clinical trials, literature, organizations, news, deals, and competitor signals. Ask any biopharma research question in natural language.

Ask a biopharma research question with Synapse Hiro LS Researcher

Questions to explore:

  • What recent publications and evidence are available on ABBV-951?
  • Which drugs, targets, indications, or clinical trials are relevant to ABBV-951?
  • What findings and limitations should be considered when researching ABBV-951?
  • Which organizations, patents, and regulatory sources provide context on ABBV-951?

Ask Synapse Hiro LS Researcher →

AI may make mistakes. Check important info.